PT MACROCITRA ARDANASEJATI

INDONESIA

HISTORY

- Founded **1991** distribute medical equipment to Indonesia Market.

- Experienced **30** years PT MACROCITRA ARDANASEJATI always provide **best service** and **quality** for laboratories and hospitals both private and government .

OUR PRODUCTS

IMPROVE®

PRE-ANALYTICAL SYSTEM

Macrocitra

PT Macrocitra Ardanasejati
Indonesia

WHO WE ARE

25

- **1996** Founded in Guangzhou, China
- **2003** **ISO** certified & **CE** marking, started to export
- **2009** IPO in China GEM; Ticker symbol: 300030
- **2010** Gel & Clot Activator Tube **US FDA** cleared, #1 FDA approved blood collection tube in China
- **2014** First oversea subsidiary founded in San Diego, U.S.A.
- **2015** Business development of services, information

IMPROVE GROUP
www.improve-med.com

Macrocitra

WHAT WE DO

Macrocitra

IMPROVE®

BECKMAN COULTER

Roche

IMPROVE®

High Compatibility

---------- Forwarded message ----------
From: Al[redacted]er@roche.com>
Date: 2017-08-18 17:32 GMT+08:00
Subject: Re: Question about IMPROVE tubes
To: "Gu[redacted]i@roche.com>
Cc: Yun[redacted]an@roche.com>,
Le[redacted]@roche.com>, Tr[redacted]ng@roche.com>

Dear Lei,
yes, all IMPROVE tubes you've sent us are qualified for LCP1. These are the following:

Vendor	Article Number /Ref. No	Cap Color	Dimensions	Tube Name	System
Improve	623050202_1	Light yellow	13x100	IMPROVE_13	LCP1
IMPROVE	623050202	Light yellow	13x100	IMPROVE_13	LCP1
Improve	161005	Light yellow	13x100	IMPROVE_13	LCP1
Improve	624070202	Light yellow	16x100	IMPROVE_09	LCP1
Improve	622030202	Intensive ochre	13x75	IMPROVE_33	LCP1
Improve		Intensive ochre	13x75	IMPROVE_33	LCP1
IMPROVE	622350202	Golden	13x75	IMPROVE_33	LCP1
IMPROVE	101620676	Golden	13x75	IMPROVE_33	LCP1
Improve	662040202	intensive green	13x75	IMPROVE_34	LCP1
IMPROVE	662040202	intensive Green	13x75	IMPROVE_34	LCP1
Improve	663050202	intensive Green	13x100	IMPROVE_21	LCP1

Abbott
A Promise for Life

SIEMENS

mindray
healthcare within reach

sysmex

Ortho Clinical Diagnostics
a Johnson & Johnson company

Stago

HOW WE DO

#1 FDA 510K

First and only FDA cleared blood collection tube

and full line of blood collection needles in China



DEPARTMENT OF HEALTH & HUMAN SERVICES — Public Health Service

Food & Drug Administration
10903 New Hampshire Avenue
Building 66
Silver Spring, MD 20993

Guangzhou Improve Medical Instruments Co., Ltd.
c/o Ms. Diana Hong
General Manager
Shanghai Midlink Business Consulting Co., Ltd.
Suite 5D, No. 19, Lane 999, Zhongshan No. 2 Road (S)
Shanghai, China 200030

JUL 12 2010

Re: k093910
Trade Name: IMPROVACUTER® Gel & Clot Activator Tube
Regulation Number: 21 CFR §862.1675
Regulation Name: Blood specimen collection devices
Regulatory Class: Class II
Product Codes: JKA
Dated: July 05, 2010
Received: July 07, 2010



DEPARTMENT OF HEALTH & HUMAN SERVICES — Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center – WO66-G609
Silver Spring, MD 20993-0002

August 27, 2013

Innovative Medical Technologies, Incorporated
Mr. Brad Brown
President
15059 Cedar Street
LEAWOOD KS 66224

Re: K123987
Trade/Device Name: Improve Blood Collection Set and Improsafe Blood Collection Set
Regulation Number: 21 CFR 880.5570
Regulation Name: Hypodermic Single Lumen Needle
Regulatory Class: II
Product Code: FMI
Dated: July 24, 2013
Received: July 26, 2013

cGMP, ISO, QSR820, Brasil GMP, KFDA, MDSAP,…

International main stream quality management system

Continues Improvement

Overall quality management & total employee involved

Main drafter of China National Standard of Vacuum Tubes Performance



WS

中华人民共和国卫生行业标准

WS/T 224—2018

真空采血管的性能验证

Performance verification of vacuum tubes for venous blood specimen

2018-04-27 发布　　2018-11-01 实施

中华人民共和国国家卫生健康委员会　发布



前　言

本标准按照GB/T 1.1-2009给出的规则起草。

本标准代替WS/T 224-2002《真空采血管及其添加剂》。

与WS/T 224-2002相比，除编辑性修改外主要变化如下：

——标准名称修改为《真空采血管的性能验证》；

——增加了真空采血管的临床评价指标（见4.4～4.6和4.8）；

——删除了原标准中部分由生产厂商测试的内容(2002年版4～7和9-13)

——修改了管体强度标准，将相对离心力提高到3000g（见4.3，2002年

本标准起草单位：广东省人民医院、中山大学孙逸仙纪念医院、广州医科大学附属第一医院、同济大学附属同济医院。

本标准主要起草人：邹伟民、李红玉、林勇平、万海英、邓冠华。

Macrocitra

Macrocitra

IMPROVE®

PRE-ANALYTICAL SYSTEM

BLOOD COLLECTION TUBE (BCT)

Serum BCT

Whole Blood BCT



Plasma BCT

ADVANTAGES OF IMPROVACUTER®

IMPROVACUTER® CORE TECHNOLOGIES



Rubber stopper

Surface treatment technology for rubber stopper

Control of pre-analytical variation

1. Surface treatment technology for rubber stopper

- **Sealing performance**
- **Decapping & Recapping**
- **Precipitates release**

- Surface treatment technology for rubber stopper is applied for
  a) keeping the vacuum: 24 months
  b) facilitating decapping and recapping
  c) preventing the precipitates releasing from rubber stopper

1. Surface treatment technology for rubber stopper

No.	Brand	Sample Qty (pcs)	Probability of cap and **stopper separation**
1	**	150	0.017 %
2	****	NA	NA, screwed cap
3	**IMPROVE**	**300**	**0.000049 %**

What is Needle Bounces?

1. Surface treatment technology for rubber stopper

No.	Brand	Sample Qty (pcs)	Probability of **needle-bounce**
1	**	150	33.9 %
2	****	125	72.6%
3	**IMPROVE**	**300**	**0**

IMPROVACUTER® CORE TECHNOLOGIES



Rubber stopper

Material

Surface treatment technology for rubber stopper

Medical polymer materials and injection molding technology

Control of pre-analytical variation

IMPROVACUTER® CORE TECHNOLOGIES

2. Medical polymer materials and injection molding technology



- Longer vacuum and liquid retention.
- Constant size compatibility with mainstream analyzers
- Relative higher temperature duration compared to other brand BCTs.
- Relative longer low temperature duration compared to other brand BCTs.

2. Medical polymer materials and injection molding technology

Comparison of different PET tubes at 60°C and RH50%

2. Medical polymer materials and injection molding technology

Comparison of different PET tubes under 70℃ by an end user in China

IMPROVE

2. Medical polymer materials and injection molding technology

Comparison of different PET tubes at -80℃

Brand	Size	Additive	Qty(pcs)	Qty of raptured tubes(pcs)			
				1h	2h	3h	24h
****	5/100	EDTAK2	20	6	6	6	6
**	5/100	EDTAK2	20	3	3	3	3
IMPROVE	5/100	EDTAK2	20	0	0	0	0

IMPROVACUTER® CORE TECHNOLOGIES

Rubber stopper → Surface treatment technology for rubber stopper

Material → Medical polymer materials and injection molding technology

Interior wall → Bionic treatment technology for tube wall

Control of pre-analytical variation

3. Bionic treatment technology for tube wall

The integrity and compactness of bionic treatment



3. Bionic treatment technology for tube wall



IMPROVACUTER® CORE TECHNOLOGIES



Rubber stopper → Surface treatment technology for rubber stopper

Material → Medical polymer materials and injection molding technology

Interior wall → Bionic treatment technology for tube wall

Clot activator

Additive → Rapid nano-clotting technology

Control of pre-analytical variation

4. Rapid nano-clotting technology

- Nano meter size SiO_2 with constant size, uniformly dispersed in the tube inner wall and mixed with blood completely to accelerate the blood coagulation cascade.

- High quality serum is obtained within **15 mins** under room temperature.

4. Rapid nano-clotting technology





Improve clot activator
200-900nm

4. Rapid nano-clotting technology



Other brand clot activator

1-3 µm, large particles with sharp edges



Improve clot activator

200-900nm, microspheres without sharp edges

IMPROVACUTER® CORE TECHNOLOGIES



Surface treatment technology for rubber stopper

Medical polymer materials and injection molding technology

Bionic treatment technology for tube wall

Rapid nano-clotting technology

Cell sleeping technology

Control of pre-analytical variation

5. Cell sleeping technology

- Cell sleeping technology inhibits cell metabolism and keep **stable plasma glucose level within 48h**.
- It provides complete protection for blood cells with less hemolysis.

IMPROVACUTER® CORE TECHNOLOGIES



Surface treatment technology for rubber stopper

Medical polymer materials and injection molding technology

Bionic treatment technology for tube wall

Rapid nano-clotting technology

Cell sleeping technology

Synthesis technology of serum / plasma gel

Control of pre-analytical variation

6. Synthesis technology of Gel

- Gel quality judgement : 1) Degree of inertia and
  2) Separation effect
- Self-control & Improvement for Gel Quality

Serum

(Density: 1.026-1.031)

Gel

(Density: 1.04-1.06)

(Density: 1.092-1.095)

Blood Cells

6. Synthesis technology of serum / plasma gel

Comparison of different Gel tubes with centrifugation in 1min after blood collection



IMPROVACUTER® POSTER Phlebotomy

IMPROVACUTER®
Venous Blood Collection System

Macrocitra

IMPROVACUTER® Tube	Additive	Test Items	Inversions
No Additive Tube or Blood Culture Bottle	/	Biochemistry Test Immunology Test	0
Citrate Tube	Sodium Citrate 0.129mol/L(3.8%) 0.109mol/L(3.2%)	Coagulation Determinations on Plasma Specimens	3~5
ESR Tube	Sodium Citrate 0.129mol/L(3.8%) 0.109mol/L(3.2%)	Erythrocyte Sedimentation Rate (ESR)	3~5
Clot Activator Tube	Clot Activator	Serum Determinations in Clinical Chemistry	5~8
Gel & Clot Activator Tube	Gel & Clot Activator	Biochemistry Test	5~8
Heparin Tube	Lithium Heparin Sodium Heparin	Plasma Determinations in Clinical Chemistry and Hemorheology	5~8
Gel & Heparin Tube	Gel & Lithium Heparin Gel & Sodium Heparin	Plasma Determinations in Clinical Chemistry	5~8
EDTA Tube	EDTA. K2 EDTA. K3	Whole Blood Hematology Determinations	Liquid: 3~5 Spray Dried: 5~8
Glucose Tube	Sodium Fluoride/EDTA Sodium Fluoride/Oxalate	Glucose Determinations	5~8
Gel & EDTA.K2 Tube	Gel & EDTA. K2	Plasma Preparation for Molecular Diagnostic and Virus Load Testing	5~8

IMPROVACUTER® tubes are recommended immediate mixing after collection
Insufficient mixing might result in inaccurate test results and the need to re-draw

*REF:NCCLS H3-A5 Vo 23. No.32, 8. 10. 2.

Storage

Storage tubes at 4-25℃ (39-77°F) , unless there is other notice on the package or label.
Do not use tubes after their expiration date.

Barrier Information

Please set refrigerated centrifuges at temperatures between **15-25℃ (59-77°F)**, and the yield of serum or plasma is ideal.

Instructions for Removal of Safety Cap

Instructions for Reinsertion of Safety Cap



Centrifugation Reference

Centrifugation RCF and Time Recommendations

Product	RCF (g)	Time (min)
No Additive Tubes	1500-2200	10
Clot Activator Tubes	1500-2200	10
Gel & Clot Activator Tubes	1800-2200	10
Plasma Tubes	1300-1800	10
Plasma Tubes with Gel	1500-1800	10
Sodium Citrate 9:1 Tubes (PT or Coagulation Tubes)	1500-2000	10

Clotting Instructions

Minimum Clotting Time Recommendations

Product	Time(min)
No Additive Tubes	60
Clot Activator Tubes	30
Gel & Clot Activator Tubes	30

86-20-32312610
dan@improve-medical.com ; info@improve-medical.com

IMPROVACUTER® Tube	Additive	Test Items	Inversions
No Additive Tube or Blood Culture Bottle	/	Biochemistry Test Immunology Test	0
Citrate Tube	Sodium Citrate 0.129mol/L(3.8%) 0.109mol/L(3.2%)	Coagulation Determinations on Plasma Specimens	3~5
ESR Tube	Sodium Citrate 0.129mol/L(3.8%) 0.109mol/L(3.2%)	Erythrocyte Sedimentation Rate (ESR)	3~5
Clot Activator Tube	Clot Activator	Serum Determinations in Clinical Chemistry	5~8
Gel & Clot Activator Tube	Gel & Clot Activator	Biochemistry Test	5~8
Heparin Tube	Lithium Heparin Sodium Heparin	Plasma Determinations in Clinical Chemistry and Hemorheology	5~8
Gel & Heparin Tube	Gel & Lithium Heparin Gel & Sodium Heparin	Plasma Determinations in Clinical Chemistry	5~8
EDTA Tube	EDTA. K2 EDTA. K3	Whole Blood Hematology Determinations	Liquid: 3~5 Spray Dried: 5~8
Glucose Tube	Sodium Fluoride/EDTA Sodium Fluoride/Oxalate	Glucose Determinations	5~8
Gel & EDTA.K2 Tube	Gel & EDTA. K2	Plasma Preparation for Molecular Diagnostic and Virus Load Testing	5~8

IMPROVACUTER® CORE TECHNOLOGIES

Jurnal Pendukung

http://dx.doi.org/10.15263/jlmsqa.2016.38.2.1

ORIGINAL ARTICLE

임상검사와 정도관리

Journal of LABORATORY MEDICINE / and QUALITY ASSURANCE

Comparison of Improvacuter EDTA Tube with BD Vacutainer EDTA Tube for Routine Hematological Analysis: Clinical Significance of Differences, Stability Study, and Effects of K_2 and K_3 EDTA

Sunyoung Ahn, Sun-Mi Cho, Hwachoon Shin, and Kyung-A Lee

Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Background: The type of blood collection tubes is an important pre-analytical factor th may affect test results. We compared the test results of the Improvacuter EDTA tube (Impro Medical, China) with those of the currently used BD Vacutainer EDTA tube (Becto Dickinson, USA) and investigated the effects of K_2 and K_3 EDTA additives.

Methods: Peripheral blood samples from 100 outpatients were collected into th aforementioned tubes. The samples were evaluated for 17 hematological analyte hemoglobin A1c, and erythrocyte sedimentation rate (ESR). The results were analysed usin the paired *t*-test for comparison. Bland-Altman plots and Passing-Bablok regressions wer used for analytes with statistically significant differences in the comparison. If the differenc were not within total allowable error, they were defined as clinically significant. For stabili testing, the initial results were compared against those from samples preserved for 72 hour

Corresponding autho
Sun-Mi Cho
Department of Labora Medicine, Gangnam S Hospital, Yonsei Unive College of Medicine, 2 ro, Gangnam-gu, Seou Korea
Tel: +82-2-2019-3775
Fax: +82-2-2019-4822
E-mail: SM178@yuhs.
pISSN: 2384-2458
eISSN: 2288-7261

loc far Laboratório de Hemoterapia e Citometria

Universidade Federal do Rio de Janeiro
Faculdade de Farmácia
Departamento de Análises Clínicas e Toxicológicas

Em, 07 de dezembro de 2009

Relatório de teste de tubos de coleta de sangue a vácuo.

Material e Métodos

Foram realizados testes em tubos de coleta de sangue a vácuo no período de 01 a 30 de novembro de 2009, procedentes de três fabricantes distintos, a saber:

1- Tubos marca BD Vacutainer contendo K2 EDTA lote nº 8310615 com validade até 03/2010.
2- Tubos marca Petrodis contendo K3 EDTA lote nº D19003 com validade até 05/2010.
3- Tubos marca Vacuplast contendo K3 EDTA lote no 081105 com validade até 10/2010.

Foram colhidas amostras de 30 pacientes e voluntários sadios que compareceram em jejum de pelo menos 3 horas, ao Laboratório de Análises Clínicas da Faculdade de Farmácia da Universidade Federal do Rio de Janeiro LACFAR – UFRJ.

Cada amostra de sangue foi coletada em cada um dos três tubos em estudo e os hemogramas automatizados foram realizados logo após a coleta e após manutenção das amostras 1 hora em temperatura de refrigerador (4° C), controlada por meio de termômetro digital.

Desta forma, cada paciente teve seu exame realizado 6 vezes. Três contagens a temperatura ambiente (TA) e três contagens a 4° C.

O equipamento utilizado para a realização dos hemogramas foi o Abbott Cell Dyn 1700. Foram confeccionadas lâminas de todos os pacientes usando sangue sem anticoagulante e utilizando as amostras de cada um das marcas em estudo em temperatura ambiente e após refrigeração. Todas as lâminas foram observadas em aumento de 1000X objetivando

Laboratório de Análises Clínicas da Faculdade de Farmácia - UFRJ
Av. Carlos Chagas Filho 373
Edifício do CCS Bloco A 2º andar sala 47
Tel. (21) 2562-6423

Clinical evaluation of Clotting Activator Tube

2017-01

1. Methods

- Comparison Test
- Under the same conditions, 3 specimens were randomly selected for clinical testing, and the total coagulation time and serum quality (Serum production volume, Secondary serum precipitation, Climbs on wall, hemolysis) of the specimens were observed.

2. Specimen Information

Item	Tube	Specification	QTY	Lot No.	Expiry Date	Product No.
Clot Activator Tube	BD	3/75	3	5232617	201612	a1、b1、c1
Clot Activator Tube	Greiner	3/75	3	A150635V	201612	a2、b2、c2
Clot Activator Tube	Improve	3/75	3	201702B	201702	a3、b3、c3
Clot Activator Tube	Some Brand	3/75	3	201702A	201702	a4、b4、c4
Clot Activator Tube	Gongdong	3/75	3	1602213	201802	a5、b5、c5

Note: All of the above products are accelerators based on inductive effects (mainly silica)

3. Pocess

- 3 volunteers as representative a, b, c, each collecting 5 tubes, randomly selected according to the above-mentioned brands, each person collects a tube of each brand;
- After the sample tube was collected, shake it upside down 5 times, stand still to observe the blood coagulation, record the clotting time and abnormalities if happened.
- After standing at room temperature (22-25 ° C) for 30-60 min, centrifuge (3000 r / min, 10 min), observe the blood state after centrifugation, whether there are cramps on the wall, precipitation, hemolysis and other abnormalities, and record the experimental results.

GUANGDONG ENTERPRISE KEY LABORATORY OF BLOOD COMPATIBILITY OF MEDICAL MATERIAL

4. Data Records and Analysis

Items / Standards / No.	Clotting time (mins)		Serum Volume		Climb on Wall		Secondary Serum Precipitation		Hemolysis		Comprehensive Evaluation
	<20min	Ava	40-60%		Assessment		Assessment		Assessment		
a1	14	12	40-60%	Good	No	Good	No	Good	No	Good	General
b1	11		40-60%		No		No		No		
c1	12		40-60%		No		No		No		
a2	9	10	40-60%		No		No		No		Good
b2	10		40-60%		No		No		No		
c2	10		40-60%		No		No		No		
a3	8	7	40-60%		No		No		No		Very Good
b3	6		40-60%		No		No		No		
c3	6		40-60%		No		No		No		
a4	14	11	40-60%		No		No		No		General
b4	9		40-60%		No		No		No		
c4	10	10	40-60%								
a5	10		40-60%								
b5	9		40-60%								
c5	10		40-60%								

5. Conclusion

In terms of the total coagulation time, t Greiner ≥ Gongdong> Improve, which shows shortest, 3-5min faster than other brands. It c reports, that is to say, the Improve Clot Activ under the same conditions than other brands

In conclusion, Improve tube (Clot Activ effect. Under the same conditions, it can prep

It is worth mentioning that the experime serum quality of all products is very good shortened to about 8 minutes, it is logically may have fibrin hanging on the wall due to serum production and quality.

DEPARTMENT OF HEALTH & HUMAN SERVIC

DE GRUYTER

Clin Chem Lab Med 2014; aop

Cevdet Zungun, Fatma Meriç Yılmaz*, Elif Guney Boru and Canan Topcuoglu

Comparison of Improvacuter™ Tubes with BD Vacutainer™ tubes for various hormones in the aspects of stability and influence of gel separators

DOI 10.1515/cclm-2014-0583
Received June 2, 2014; accepted July 21, 2014

Abstract

Background: Validation of blood collection tubes are important to determine the role of different collection tubes which influence the assurance of laboratory results. We compared two different tubes (Improvacuter™ and Becton Dickinson [BD] Vacutainer™) and investigated the effect of gel and storage time in comparison with each other.

Methods: We compared the results of nine immunoassays performed on UniCel® DxI 800 using blood samples collected in BD Vacutainer SST II Advance tubes, Improvacuter Gel and Clot Activator tubes, BD Vacutainer Clot Activator tubes and Improvacuter tubes. Analytes were measured in all tubes on 3 consecutive days to study the effect of long-term storage. Evaluation of clinical significance was performed based on total allowable error.

Results: Estradiol and testosterone concentrations obtained from Improvacuter Gel and Clot Activator tubes and BD Vacutainer SST II Advance tubes remained below gel containing tubes for estradiol and testosterone are not recommended on UniCel® DxI 800 according to our results. The change in the analyte concentrations over 48 h remained within the TE_a limits for the studied analytes. Improve tubes gave similar results to BD tubes.

Keywords: BD Vacutainer; gel separator tube; hormone assay; improvacuter; stability.

Introduction

In order to minimize preanalytical errors due to prolonged contact of serum with blood cells, Clinical and Laboratory Standards Institute (CLSI) recommends performing the analysis within 2 h following blood collection [1]. The use of serum separator gels has found acceptance among clinical laboratories since they were manufactured and introduced approximately 40 years ago by Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA). The separator gel formation which is made from polymeric material provides some benefits due to its specific density [2]. The

September 12, 2016

Guangzhou Improve Medical Instruments Co., Ltd.
% Dianna Hong
General Manager
Mid-Link Consulting Co., Ltd
P.O. Box 120-119
Shanghai, 200120 CHINA

Re: K153388
Trade/Device Name: IMPROSAFE® Blood Collection Set With Pre-attached Holder, IMPROVACUTER® Blood Collection Set Pre-attached Holder, IMPROSAFE® Blood Collection Set, IMPROVACUTER® Blood Collection Set, IMPROSAFE® Multi Sample Needle, IMPROSAFE® Multi Sample Needle (flashback), IMPROVACUTER® Multi Sample Needle
Regulation Number: 21 CFR 880.5570
Regulation Name: Hypodermic Single Lumen Needle
Regulatory Class: Class II
Product Code: FMI
Dated: November 3, 2015
Received: February 23, 2016

Dear Dianna Hong:

This letter corrects our substantially equivalent letter of June 7, 2016.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be

Phlebotomy Training



- Pelatihan Flebotomi untuk meningkatkan keahlian dan keterampilan dari para analis maupun perawat dalam pengambilan sampel
- Mengurangi faktor kesalahan teknis dan kegagalan pengambilan sampel

IMPROVACUTER® CORE TECHNOLOGIES

Customers

- St. Carolous Hospital
- Red Cross (PMI)
- Pramita Laboratorium Klinik
- Biotest Laboratorium Klinik
- Tirta Medical Center
- Sahid Sahirman Hospital
- RS Patria IKKT
- RS Yarsi, Jakarta
- Laboratorium Klinik Daya Medika
- Omni Hospital
- RSAU Hasan Toto
- Abdul Moeloek Hospital
- RS Hermina Group
- RS PGI Cikini
- RS Ciputra Group
- Kalgen Innolab
- Mayapada Clinic, dll
- dan yang berikutnya **ANDA**

TERIMA KASIH

Macrocitra

IMPROVACUTER® CORE TECHNOLOGIES

Info lebih lanjut :

Tommy

0812-9108-0077



https://forms.gle/v1egmmY1VCF5tjhv6